Orange Book product · Generic (ANDA)
FOSAPREPITANT DIMEGLUMINE
FOSAPREPITANT DIMEGLUMINE
At a glance
Sep 05, 2019
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 05, 2019
6 yr 11 mo ago
Today
Pharmaceutical detail
Active ingredient
FOSAPREPITANT DIMEGLUMINE
Strength
EQ 150MG BASE/VIAL
Dosage form
POWDER
Route
INTRAVENOUS
TE code
Not listed
Application
ANDA 210689
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of FOSAPREPITANT DIMEGLUMINE
- 2023FOCINVEZBrand (NDA)
NDA 216686 · STERISCIENCE
- 2019FOSAPREPITANT DIMEGLUMINEBrand (NDA)
NDA 210064 · TEVA PHARMS USA
- 2008EMENDBrand (NDA)
NDA 022023 · MERCK AND CO INC
- 2023FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 214683 · PIRAMAL CRITICAL
- 2021FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 213199 · PRAXGEN
- 2021FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 214616 · ASPIRO
- 2021FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 212143 · CHIA TAI TIANQING
- 2021FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 210625 · EUGIA PHARMA
- 2020FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 211160 · DR REDDYS
- 2020FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 203939 · CAPLIN
- 2020FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 213106 · QILU PHARM HAINAN
- 2020FOSAPREPITANT DIMEGLUMINEGeneric (ANDA)
ANDA 204025 · ACCORD HLTHCARE
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
